Chilton Capital Management LLC Has $10.91 Million Holdings in Merck & Co., Inc. (MRK)

Chilton Capital Management LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 222.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 170,237 shares of the company’s stock after buying an additional 117,383 shares during the quarter. Chilton Capital Management LLC’s holdings in Merck & Co., Inc. were worth $10,910,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in MRK. Northeast Financial Consultants Inc bought a new stake in shares of Merck & Co., Inc. during the 1st quarter worth about $222,000. Oxbow Advisors LLC raised its position in shares of Merck & Co., Inc. by 18.8% during the 1st quarter. Oxbow Advisors LLC now owns 11,495 shares of the company’s stock worth $730,000 after buying an additional 1,820 shares in the last quarter. Rockefeller Financial Services Inc. raised its position in shares of Merck & Co., Inc. by 0.3% during the 1st quarter. Rockefeller Financial Services Inc. now owns 504,510 shares of the company’s stock worth $32,057,000 after buying an additional 1,429 shares in the last quarter. Linscomb & Williams Inc. raised its position in shares of Merck & Co., Inc. by 8.5% during the 1st quarter. Linscomb & Williams Inc. now owns 71,518 shares of the company’s stock worth $4,544,000 after buying an additional 5,580 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Merck & Co., Inc. by 70.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock worth $353,841,000 after buying an additional 2,300,200 shares in the last quarter. Institutional investors own 73.84% of the company’s stock.

Merck & Co., Inc. (NYSE MRK) traded up $0.80 during trading on Monday, hitting $55.57. 10,423,300 shares of the stock traded hands, compared to its average volume of 9,727,585. The stock has a market capitalization of $151,342.47, a P/E ratio of 14.28, a P/E/G ratio of 2.57 and a beta of 0.76. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. Merck & Co., Inc. has a 1-year low of $53.63 and a 1-year high of $66.80.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the firm posted $1.07 earnings per share. research analysts predict that Merck & Co., Inc. will post 3.95 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 8th. Investors of record on Friday, December 15th will be given a dividend of $0.48 per share. The ex-dividend date is Thursday, December 14th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.47. This represents a $1.92 dividend on an annualized basis and a yield of 3.46%. Merck & Co., Inc.’s payout ratio is presently 112.58%.

Merck & Co., Inc. announced that its board has approved a stock buyback program on Tuesday, November 28th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

MRK has been the topic of a number of research reports. Jefferies Group reiterated a “sell” rating and issued a $52.00 target price on shares of Merck & Co., Inc. in a report on Sunday, August 20th. Credit Suisse Group dropped their target price on shares of Merck & Co., Inc. from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. Cowen reiterated a “hold” rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a report on Friday, September 1st. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 target price on shares of Merck & Co., Inc. in a report on Friday, September 8th. Finally, Zacks Investment Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $66.29.

In related news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.25% of the company’s stock.

WARNING: “Chilton Capital Management LLC Has $10.91 Million Holdings in Merck & Co., Inc. (MRK)” was reported by Zolmax and is the sole property of of Zolmax. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://zolmax.com/investing/chilton-capital-management-llc-has-10-91-million-holdings-in-merck-co-inc-mrk/1838021.html.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Westlake Chemical  Earns Daily Coverage Optimism Score of 0.07
Westlake Chemical Earns Daily Coverage Optimism Score of 0.07
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng Stock Price
SVB Financial Group  Given News Impact Score of 0.43
SVB Financial Group Given News Impact Score of 0.43
CVR Partners LP  Given Consensus Recommendation of “Hold” by Brokerages
CVR Partners LP Given Consensus Recommendation of “Hold” by Brokerages
Prologis  Earns Daily Media Sentiment Rating of 0.06
Prologis Earns Daily Media Sentiment Rating of 0.06
KKR & Co. L.P.  Receiving Somewhat Favorable News Coverage, Report Shows
KKR & Co. L.P. Receiving Somewhat Favorable News Coverage, Report Shows


Leave a Reply

 
© 2006-2018 Zolmax.